Large Molecule

Biotechs to Benefit from $2B Government Ebola Contracts

Source: Bloomberg

Nov 11, 2014

Bloomberg

Multiple drugmakers involved in Ebola treatment will potentially share in $2B worth of what will likely be no-bid contract awards, as part of the $6.2 billion in emergency funding Obama asked for last week.

Several drugmakers -- including Mapp Biopharmaceutical, Johnson & Johnson, Emergent Biosolutions, NewLink Genetics and Novavax -- are currently working on vaccines and/or drugs that target the infection.

To date, there is limited public access to information pertaining to which companies have received Ebola-specific funding from the U.S. government. Congress has previously approved $838 million toward Ebola relief efforts, of which $77 million has been awarded in contracts so far this year.

Read the Bloomberg press release